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OBJECTIVE—Antecedent hypoglycemia can blunt neuroendo-
crine and autonomic nervous system responses to next-day
exercise in type 1 diabetes. The aim of this study was to
determine whether antecedent increase of plasma cortisol is a
mechanism responsible for this ﬁnding.
RESEARCH DESIGN AND METHODS—For this study, 22
type 1 diabetic subjects (11 men and 11 women, age 27  2 years,
BMI 24  1 kg/m
2, A1C 7.9  0.2%) underwent four separate
randomized 2-day protocols, with overnight normalization of
blood glucose. Day 1 consisted of morning and afternoon 2-h
hyperinsulinemic- (9 pmol  kg
1  min
1) euglycemic clamps (5.1
mmol/l), hypoglycemic clamps (2.9 mmol/l), or euglycemic
clamps with a physiologic low-dose intravenous infusion of
cortisol to reproduce levels found during hypoglycemia or a
high-dose infusion, which resulted in further twofold greater
elevations of plasma cortisol. Day 2 consisted of 90-min eugly-
cemic cycling exercise at 50% VO2max.
RESULTS—During exercise, glucose levels were equivalently
clamped at 5.1  0.1 mmol/l and insulin was allowed to fall to
similar levels. Glucagon, growth hormone, epinephrine, norepi-
nephrine, and pancreatic polypeptide responses during day 2
exercise were signiﬁcantly blunted following antecedent hypo-
glycemia, low- and high-dose cortisol, compared with antecedent
euglycemia. Endogenous glucose production and lipolysis were
also signiﬁcantly reduced following day 1 low- and high-dose
cortisol.
CONCLUSIONS—Antecedent physiologic increases in cortisol
(equivalent to levels occurring during hypoglycemia) resulted in
blunted neuroendocrine, autonomic nervous system, and meta-
bolic counterregulatory responses during subsequent exercise in
subjects with type 1 diabetes. These data suggest that prior
elevations of cortisol may play a role in the development of
exercise-related counterregulatory failure in those with type 1
diabetes. Diabetes 58:2100–2108, 2009
T
he Diabetes Control and Complications Trial has
deﬁnitively demonstrated that intensive glyce-
mic control can reduce microvascular complica-
tions in those with type 1 diabetes (1). However,
intensive therapy is associated with an increased inci-
dence of hypoglycemia (2). Exercise is a cornerstone of
diabetes management. It improves insulin sensitivity,
helps in body weight maintenance, and lowers the risk of
cardiovascular disease. Unfortunately, exercise is associ-
ated with an increased prevalence of hypoglycemia in
patients with diabetes. Furthermore, fear of hypoglycemia
results in a serious limitation to the widespread implemen-
tation of intensive glycemic control and exercise.
Previous studies have shown that antecedent hypogly-
cemia can blunt neuroendocrine, autonomic nervous sys-
tem (ANS), and metabolic counterregulatory responses to
subsequent exercise (3,4). Reciprocally, antecedent exer-
cise can also blunt homeostatic counterregulatory re-
sponses to subsequent hypoglycemia (5,6). Therefore,
vicious cycles can be created in type 1 diabetes where an
episode of hypoglycemia or exercise can downregulate
counterregulatory responses to a subsequent episode of
either stress, thereby increasing the risk for further hypo-
glycemia. However, the mechanisms responsible for exer-
cise-associated counterregulatory failure are not known.
Multiple studies have demonstrated that antecedent in-
creases of corticosteroids can blunt subsequent ANS and
neuroendocrine responses to a wide spectrum of differing
antecedent stress (7–21). Previous studies have also dem-
onstrated that pharmacologic antecedent increases of
cortisol can blunt counterregulatory responses to subse-
quent hypoglycemia in normal subjects (a stress that
defends against a falling plasma glucose with similar
counterregulatory responses compared with exercise) (7–
8). Although, the question of whether physiologic levels of
cortisol can blunt counterregulatory responses to subse-
quent hypoglycemia is still undecided (15,22–24). How-
ever, studies speciﬁcally investigating the effects of prior
elevations of corticosteroids on counterregulatory mech-
anisms during exercise are lacking. Furthermore, no study
has investigated the mechanisms responsible for exercise-
related counterregulatory failure in the clinically relevant
group of those with type 1 diabetes.
Therefore, the speciﬁc aim of this present study was to
test the hypothesis that antecedent physiologic or phar-
macologic elevations of cortisol could blunt counterregu-
latory responses during subsequent submaximal exercise
in type 1 diabetic individuals. To test this hypothesis,
hydrocortisone was administered intravenously on day
1 during hyperinsulinemic-euglycemic clamps and re-
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during the following day.
RESEARCH DESIGN AND METHODS
We studied 22 patients with type 1 diabetes (11 men and 11 women), age 27 
2 years, BMI 24  1 kg/m
2, and A1C 7.9  0.2% (normal range 4–6.5%).
Patients had been diagnosed with type 1 diabetes for 12  2 years and had no
clinical evidence of tissue complications of the disease such as retinopathy,
renal impairment, or autonomic neuropathy. Patients were treated with either
multiple daily injections of insulin or continuous subcutaneous insulin via a
pump. Each patient had normal blood count, plasma electrolytes, and liver
function. All gave written informed consent. Studies were approved by the
Vanderbilt University human subjects institutional review board.
At least two weeks before the initial study, patients performed an incre-
mental work test on a stationary cycle ergometer to determine VO2max and
anaerobic threshold (AT). Airﬂow, O2, and CO2 concentrations in inspired and
expired air were measured by a computerized open-circuit indirect colorimet-
ric cart (Parvo Medics, Kansas City, MO) with a mouthpiece and nose clip
system. AT was determined by the V-slope method (25). AT determined by gas
exchange corresponds to the onset of an increased lactate/pyruvate ratio in
blood and indicates the level of exercise above which anaerobic mechanisms
supplement aerobic energy production (25). At workloads below the AT,
exercise can be continued for a prolonged period, whereas above the AT,
fatigue will occur considerably faster (25). The experimental work rate was
established by calculating 80% AT, which responded to 47  2% of the
subject’s VO2max. This workload was chosen because it is close enough to the
AT to produce a physically challenging stress (i.e., large experimental signal)
but is sustainable for a prolonged period of time. Subjects studied ranged from
sedentary to regularly exercising, although not actively participating in com-
petitive sports. Mean VO2max for the group was 34  2m l kg
1  min
1 (range
24–51 ml  kg
1  min
1).
Type 1 diabetic subjects were studied during four separate 2-day studies.
Day 1 consisted of morning and afternoon 2-h hyperinsulinemic-euglycemic
clamps (anteEugly), hypoglycemic clamps (anteHypo), or euglycemic clamps
with cortisol infusion at 1 g  kg
1  min
1 (anteCort1) or 2 g  kg
1  min
1
(anteCort2). Day 2 was identical for all four protocols and consisted of 90-min
euglycemic cycling exercise.
Patients were asked to avoid hypoglycemia during the 7 days preceding
each visit. Patients checked blood glucose levels at least four times per day
and reported values to the investigators before admission. Detection of any
value 3.9 mmol/l resulted in rescheduling of the study. Patients were also
asked to avoid exercise and consume a usual weight-maintaining diet for 3
days before each study. Each subject was admitted to the Vanderbilt Clinical
Research Center on the afternoon before an experiment. Upon admission,
patients were asked to discontinue usual insulin therapy, and two intravenous
cannulas were inserted under 1% lidocaine local anesthesia. One cannula was
placed in a retrograde fashion into a vein on the back of one hand. This hand
was placed in a heated box (55–60°C) so that arterialized blood could be
obtained (26). The other cannula was placed in the contra lateral arm for
infusion of dextrose, insulin, potassium chloride, hydrocortisone, and tritiated
glucose during the study. Intravenous infusion of Humulin R (Eli Lilly,
Indianapolis, IN) was started at a basal rate via a variable rate volumetric
infusion pump (Imed, San Diego, CA). Patients then consumed a standardized
dinner and 9:00 P.M. snack and were requested not to ingest any food after
10:00 P.M. The insulin infusion rate was increased during meal consumption.
Throughout the night, glucose was measured every 30 min and the insulin
infusion rate was adjusted to maintain blood glucose between 4.4–6.7 mmol/l.
Day 1 procedures. The protocol consisted of an initial period (0–120 min to
simulate the isotope equilibration period of day 2), a morning hyperinsuline-
mic glucose clamp (120–240 min), a rest period (240–360 min), and an
afternoon hyperinsulinemic glucose clamp (360–480 min). At 120 min in all
studies, a primed continuous infusion of insulin (9 pmol  kg
1  min
1) was
started via a Medfusion 3010 pump (Medex-A Furon Healthcare Company,
Deluth, GA). Potassium chloride (5 mmol/h) was also infused during each
clamp period to reduce insulin-induced hypokalemia. Plasma glucose was
measured every 5 min and maintained at the desired level via a variable rate
infusion of 20% dextrose via an Imed pump (27). In anteEugly studies, plasma
glucose was held constant at basal levels (5 mmol/l). In anteHypo studies,
plasma glucose was allowed to fall over a 30-min period to a target hypogly-
cemic plateau of 2.9 mmol/l. In anteCort studies, plasma glucose was held at
euglycemia together with a constant 2-h intravenous physiologic infusion of
cortisol of 1 g  kg
1  min
1 (anteCort1) or pharmacologic infusion at 2 g 
kg
1  min
1 (anteCort2). Thus, in the two latter protocols, the effects of an
increase of plasma cortisol, independent of hypoglycemia, on subsequent
counterregulatory responses during exercise could be determinined. At 240
min, the insulin infusion was decreased to the basal rate; euglycemia was
restored in anteHypo studies or maintained in anteEugly and anteCort studies.
At 360 min, a second 2-h clamp identical to that in the morning was performed.
At 480 min, the insulin infusion was decreased to the basal rate; euglycemia
was again restored or maintained, and patients were allowed to consume a
standardized meal. Evening and overnight procedures were then identical to
those of admission night.
Day 2 procedures. Day 2 procedures were identical for all four protocols.
The experiments lasted 210 min and consisted of a tracer equilibration (0–90
min), basal (90–120 min), and exercise (120–210 min). A primed (18 Ci)
continuous infusion (0.8 Ci/min) of high-performance liquid chromatog-
raphy–puriﬁed [3-
3H] glucose (Perkin Elmer Life Sciences, Boston, MA; 11.5
mCi  mmol
1  l
1) was started at 0 min and continued throughout the study
to measure glucose kinetics. Exercise consisted of 90 min continuous cycling
(at 60–70 rpm) on an upright cycle ergometer (Medical Graphics, Yorba Linda,
LA) at 80% of the individual’s AT (50% VO2max). During exercise, the basal
insulin infusion rate was adjusted down or maintained at 1 unit/h. This rate of
insulin infusion has been shown to reproduce basal levels of insulin (60  6
pmol/l) throughout the 90-min cycling exercise (3). Plasma glucose was
measured every 5 min and maintained at basal levels (5 mmol/l) throughout
the study via a variable rate infusion of 20% dextrose. After completion of the
exercise protocol, patients consumed a meal and were discharged.
Tracer methodology. Rates of glucose appearance, endogenous glucose
production (EGP), and glucose utilization were calculated according to the
method of Wall et al. (28). EGP was calculated by determining the total rate
of glucose appearance (which comprises both EGP and any exogenous
glucose infused to maintain euglycemia) and subtracting from it the amount of
exogenous glucose infused. It is now recognized that this approach is not fully
quantitative because underestimates of total rate of glucose appearance and
rates of glucose disposal can be obtained. This underestimate can be largely
overcome by use of a highly puriﬁed tracer and taking measurements under
steady-state conditions (i.e., constant glucose-speciﬁc activity). To minimize
changes in speciﬁc activity, the tracer infusion rate was gradually doubled
during the ﬁrst 30 min of exercise. During the last 60 min of exercise,
proportional additional increases of tracer delivery were made commensurate
with changes of the exogenous glucose infusion rate.
Analytical methods. Plasma glucose concentrations were measured in
triplicate using the glucose oxidase method with a glucose analyzer (Beck-
man, Fullerton, CA). Blood for hormones and intermediary metabolites was
drawn twice during the basal period and every 15–30 min during the clamp
period. Glucagon was measured according to the method of Aguilar-Parada,
Eisentraut, and Unger (29) with an interassay coefﬁcient of variation (CV) of
15% free. Insulin was measured after polyethelene glycol extraction as
previously described (30) with an interassay CV of 11%. Catecholamines were
determined by high-pressure liquid chromatography (31) with an interassay
CV of 12% for both epinephrine and norepinephrine. We made two modiﬁca-
tions to the procedure for catecholamine determination: 1) we used a
ﬁve-point rather than one-point standard calibration curve; 2) we spiked the
initial and ﬁnal samples of plasma with known amounts of epinephrine and
norepinephrine so that accurate identiﬁcation of the relevant catecholamine
peaks could be made. Cortisol was assayed using the Clinical Assays Gamma
Coat Radioimmunoassay (RIA) kit with an interassay CV of 6%. Growth
hormone was determinined by RIA (32) with an interassay CV of 8%.
Pancreatic polypeptide was measured by RIA using the method of Hagopian et
al. (33) with an interassay CV of 8%. Lactate, glycerol, alanine, and -hydroxy-
butyrate were measured on deproteinized whole blood using the method of
Lloyd et al. (34). Nonesteriﬁed fatty acids (NEFAs) were measured using the
WAKO kit adopted for use on a centrifugal analyzer (35). Cardiovascular
parameters (heart rate and systolic and diastolic blood pressure) were
measured every 10 min during clamp studies. Hypoglycemic symptoms were
quantiﬁed using a previously validated semiquantitative questionnaire (36).
Each individual was asked to rate his/her experience of the symptoms twice
during the control period and every 15 min during experimental periods.
Symptoms measured included sweaty, tremor/shaky, hot, thirsty/dry mouth,
agitation/irritability, palpitations, tired/fatigued, confusion/dizzy/difﬁculty
thinking, blurriness of vision, and sleepy. The ratings of the ﬁrst six symptoms
were summed to get the autonomic score, whereas the ratings from the last
six symptoms provide a neuroglycopenic symptom score.
Statistical analysis. Data are expressed as means  SE and were analyzed
using parametric two-way analysis of variance with repeated measures.
Tukey’s post hoc analysis or Student’s t tests were used to delineate statistical
signiﬁcance across time within each group and for anteHypo or anteCort
group compared with the anteEugly control group. A P value of 0.05 was
accepted as statistically signiﬁcant. The baseline and ﬁnal 30 min of exercise
on day 2 were compared for most parameters. Baseline data represent an
average of two time points (110 and 120 min), and the ﬁnal 30-min data
represent an average of three measures taken during this time (180, 195, and
210 min).
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Day 1
Plasma glucose, insulin, cortisol levels, epinephrine,
and symptom responses. Basal plasma glucose levels
were similar among the four experimental groups (Table
1). During the ﬁnal 30 min of clamp studies, plasma
glucose levels were similar between anteEugly, anteCort1,
and anteCort2. Plasma insulin levels were also similar
among the four experimental groups during basal periods
and during the ﬁnal 30 min of clamp studies (Table 1).
Morning basal cortisol levels were similar among the four
experimental groups (Table 1). During antecedent hypo-
glycemia and low-dose cortisol infusion (anteCort1), there
were equivalent increases in day 1 morning and afternoon
plasma cortisol levels. High-dose cortisol (anteCort2) re-
sulted in approximately twofold greater levels of the
hormone during the ﬁnal 30 min of morning and afternoon
clamps compared with anteHypo and anteCort1. During
anteHypo, plasma epinephrine increased from basal levels
of 148  37 to 2,718  427 pmol/l and symptoms increased
from 17  3t o5 4 18.
Day 2
Glucose, insulin, and counterregulatory hormone
levels. Basal plasma glucose levels were similar among
the four experimental groups (anteEugly [5.2  0.1
mmol/l], anteHypo [5.2  0.1 mmol/l], anteCort1 [5.5  0.1
mmol/l], and anteCort2 [5.4  0.1 mmol/l]) and were
maintained equivalently throughout exercise (Fig. 1).
Basal plasma insulin levels were similar among the four
experimental groups (anteEugly [98  16 pmol/l], ante-
Hypo [102  16 pmol/l], anteCort1 [108  22 pmol/l], and
anteCort2 [107  14 pmol/l]). During exercise, plasma
insulin levels were allowed to fall similarly in a physiologic
manner among the four groups (anteEugly [82  11
pmol/l], anteHypo [84  11 pmol/l], anteCort1 [90  23
pmol/l], and anteCort2 [89  10 pmol/l]; Fig. 1).
Basal values of glucagon, growth hormone, and cortisol
were similar at the start of each protocol (Table 2).
Incremental increases of glucagon were reduced during
the ﬁnal 30 min of exercise in anteHypo (4  2 ng/l),
anteCort1 (1  3 ng/l), and anteCort2 (2  1 ng/l)
compared with anteEugly (9  2 ng/l; P  0.05; Fig. 2).
Incremental increases of growth hormone were also re-
duced during the ﬁnal 30 min of exercise in anteHypo (3 
1 g/l), anteCort1 (4  1 g/l), and anteCort2 (4  2 g/l)
compared with anteEugly (9  2 g/l; P  0.05; Fig. 3).
Exercise-induced increments in cortisol were less (P 
0.05) in anteHypo (74  44 nmol/l), anteCort1 (35  20
nmol/l), and anteCort2 (73  52 nmol/l) compared with
anteEugly (204  63 nmol/l) (Fig. 2).
Basal values of epinephrine, norepinephrine, and pan-
creatic polypeptide were similar at the start of each
protocol (Table 2). ANS responses during exercise were
also reduced by day 1 antecedent hypoglycemia and
cortisol infusions. Incremental increases of epinephrine
were reduced during the ﬁnal 30 min of exercise in
anteHypo (316  60 pmol/l), anteCort1 (212  31 pmol/l),
and anteCort2 (354  66 pmol/l) compared with anteEugly
(582  101 pmol/l; P  0.05; Fig. 3). Exercise-induced
increments of norepinephrine were also less in anteHypo
(2.2  0.4 nmol/l), anteCort1 (2.0  0.2 nmol/l), and
anteCort2 (2.0  0.3 nmol/l) compared with anteEugly
(4.0  0.5 nmol/l; P  0.05; Fig. 3). Incremental increases
of pancreatic polypeptide from baseline were also blunted
during the ﬁnal 30 min of exercise in anteHypo (7.4  2
pg/l), anteCort1 (4.0  1.4 pg/l), and anteCort2 (7.5  2
pg/l) compared with anteEugly (17  5 pg/l; P  0.05; Fig.
2).
Glucose kinetics. During the ﬁnal 30 min of exercise, the
exogenous glucose infusion rates used to maintain eugly-
cemia were signiﬁcantly higher in anteHypo (19  2 mol 
kg
1  min
1), anteCort1 (20  4 mol  kg
1  min
1), and
anteCort2 (19  3 mol  kg
1  min
1) compared with
anteEugly (11  2 mol  kg
1  min
1; P  0.05; Fig. 4).
EGP was signiﬁcantly lower in anteCort1 (11  2 mol 
kg
1  min
1) and anteCort2 (14  2 mol  kg
1  min
1)
compared with anteEugly (22  3 mol  kg
1  min
1; P 
0.05; Fig. 4).
Intermediary metabolism. Basal levels of lactate, ala-
nine, -hydroxybutyrate glycerol, and NEFA levels were
TABLE 1
Plasma glucose, insulin, and cortisol levels during two 2-h hyperinsulinemic-euglycemic clamps (anteEugly), hypoglycemic clamps
(anteHypo), or euglycemic clamps with intravenous cortisol infusions of 1 g  kg
1  min
1 (anteCort1) or 2 g  kg
1  min
1
(anteCort2) on day 1
Morning clamp Afternoon clamp
Basal
Final 30 min of
exercise Basal
Final 30 min of
exercise
Plasma glucose (mmol/l)
anteEugly 5.4  0.1 5.0  0.1 5.3  0.1 5.2  0.1
anteHypo 5.3  0.1 2.9  0.1* 5.2  0.1 2.9  0.1*
anteCort1 5.4  0.1 5.0  0.1 5.5  0.1 5.1  0.1
anteCort2 5.4  0.1 5.1  0.1 5.5  0.1 5.2  0.1
Plasma insulin (pmol/l)
anteEugly 94  15 588  33 60  12 588  42
anteHypo 90  15 576  36 58  9 606  39
anteCort1 108  17 606  77 93  19 588  72
anteCort2 93  15 582  41 66  15 602  47
Plasma Cortisol (nmol/l)
anteEugly 419  69 328  48 290  46 301  35
anteHypo 374  47 696  96* 351  46 702  98*
anteCort1 341  39 720  39* 343  39 703  41*
anteCort2 469  55 1,202  70*† 579  60*† 1,216  70*†
Data are means  SEM. n  22 patients (11 men/11 women) with type 1 diabetes. *Signiﬁcant difference versus anteEugly. †Signiﬁcant
difference versus anteHypo and anteCort1 (P  0.05).
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different responses of intermediary metabolites during day
2 exercise. Following day 1 hypoglycemia, anteCort1, and
anteCort2, glyerol and NEFA responses during exercise
were reduced compared with anteEugly (P  0.05).
Plasma lactate responses were also reduced during exer-
cise following day 1 anteHypo and anteCort1 (P  0.05).
-Hydroxybutyrate levels did not signiﬁcantly increase
during exercise following anteHypo and anteCort1 and fell
following anteCort2 (Table 3).
Cardiovascular parameters. Heart rate and systolic
and diastolic blood pressure were similar at baseline
and changed similarly during exercise in all four groups
(Table 4).
DISCUSSION
This study has investigated the mechanism(s) responsible
for exercise-associated counterregulatory failure in those
with type 1 diabetes. Our results demonstrate that ante-
cedent physiologic and pharmacologic levels of plasma
cortisol similar to prior hypoglycemia result in widespread
blunting of neuroendocrine, ANS, and metabolic re-
sponses during next-day moderate-intensity exercise in
subjects with type 1 diabetes.
Exercise-associated hypoglycemia is a signiﬁcant clini-
cal problem in patients with type 1 diabetes. In fact, recent
work has reported that patients will overcompensate
following episodes of hypoglycemia by excessively de-
creasing insulin and subsequently compromising glycemic
control with increases in A1C. These actions then lead to
paradoxical deterioration of glycemic control rather than
the expected improvements in A1C following exercise
(37). We and others have demonstrated that antecedent
hypoglycemia and exercise can establish reciprocal feed-
forward vicious cycles that cause downregulation of ANS
and neuroendocrine counterregulatory response during
each subsequent stress (4,6,38,39). However, the speciﬁc
mechanisms responsible for the failure of these physio-
logic counterregulatory mechanisms are not known. Thus,
this study was conducted with the aim of providing knowl-
edge regarding the mechanisms responsible for the inability
of type 1 diabetic individuals to defend plasma glucose
during exercise following antecedent hypoglycemia.
Glucose levels were carefully controlled at all times
during the 2-day studies. Hypoglycemia was avoided dur-
ing the overnight stays in our clinical research center so
that the effects of antecedent cortisol on subsequent
exercise could be clearly determined. Additionally, plasma
glucose levels were clamped equivalently during all four
protocols. This is important because during exercise hy-
perglycemia reduces, whereas even minimal reductions in
plasma glucose can amplify, some neuroendocrine re-
sponses (40). Insulin levels were also carefully controlled
during the clamp studies. During exercise the insulin
levels were equated and were reduced to simulate the
usual physiologic fall that occurs in nondiabetic individu-
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FIG. 1. Plasma glucose (A) and insulin (B) concentrations (means 
SE) during day 2 euglycemic exercise studies in 22 patients (11 men/11
women) with type 1 diabetes. On the previous day, patients had
undergone two 120-min euglycemic clamps (F, anteEugly), hypoglyce-
mic clamps (f, anteHypo), or euglycemic clamps with intravenous
cortisol infusions at 1 g  kg
1  min
1 (Œ, anteCort1) or 2 g  kg
1 
min
1 ( , anteCort2) on day 1. Plasma glucose and insulin levels were
comparable among the four experimental groups during basal and
exercise periods.
TABLE 2
Basal value for counterregulatory hormones at the start of day 2 exercise after two 120-min euglycemic clamps (anteEugly),
hypoglycemic clamps (anteHypo), or euglycemic clamps with intravenous cortisol infusions of 1 g  kg
1  min
1 (anteCort) or 2
g  kg
1  min
1 (anteCort2) on day 1
anteEugly anteHypo anteCort1 anteCort2
Epinephrine (pmol/l) 279  55 225  38 290  55 230  33
Norepinephrine (nmol/l) 1.6  0.2 1.4  0.2 1.3  0.2 1.2  0.1
Pancreatic polypeptide (pmol/l) 16  31 9  62 1  62 0  4
Glucagon (ng/l) 44  34 5  45 4  10 43  3
Growth hormone (g/l) 4  34  22  12  1
Cortisol (nmol/l) 359  55 367  47 286  62 442  59
Data are means  SEM. n  22 type 1 diabetic subjects (11 men/11 women).
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of our experimental design because it allows determina-
tion of the effects of the antecedent corticosteroid on
subsequent exercise in the presence of low (and reducing)
levels of insulin. Secondly, the inability to suppress insulin
levels during exercise in those with type 1 diabetes is
recognized as an important causative factor for exercise-
induced hypoglycemia (41).
There are numerous reports of prior increases of corti-
costeroids blunting subsequent physiologic responses to
a wide variety of differing physiologic stress (7–21). It
is unknown whether prior increases of corticosteroids
can blunt subsequent homeostatic/counterregulatory re-
sponses to exercise. In this present study, we clearly
demonstrate that antecedent increases of both physiologic
(by matching the increase of cortisol occurring during
prior hypoglycemia) and pharmacologic levels of cortisol
can substantially reduce counterregulatory response dur-
ing next-day submaximal exercise.
In subjects with type 1 diabetes, glucagon responses
to hypoglycemia are gradually lost over the ﬁrst few
years following diagnosis. However, glucagon release
during exercise is preserved, indicating that the pancre-
atic -cell deﬁcit is stimulus speciﬁc. After antecedent
euglycemia, our patients were able to mount a glucagon
response similar to that previously observed in nondia-
betic subjects during exercise of similar duration and
intensity (4). Day 1 hypoglycemia signiﬁcantly reduced
the glucagon response to subsequent exercise. Both
prior physiologic (anteCort1) and pharmacologic (ante-
Cort2) cortisol elevation without hypoglycemia also
resulted in similar glucagon-blunting effects. The regu-
lation of glucagon release during exercise is controver-
sial. There are data both for and against ANS regulation
of the hormone during exercise (42,43). However, of the
studies reporting positive modulation of glucagon re-
lease by ANS during exercise, there is debate whether
regulation occurs via sympathetic or parasympathetic
nervous system mechanisms (42). In this present study,
prior physiologic and pharmacologic increases of corti-
sol had similar effects to downregulate branches of ANS
activity during exercise. Epinephrine (adrenomedul-
lary), norepinephrine (sympathetic neural), and pancre-
atic polypeptide (also -adrenoreceptor sympathetic
nervous system mediated during exercise [44]) were all
blunted by antecedent low- and high-dose cortisol.
Additionally, a direct effect of epinephrine on glucagon
release has also been proposed. Thus, absent an effect
of cortisol to directly inhibit glucagon release from
pancreatic -cells, it would appear that the blunted
response of the hormone following low- and high-dose
cortisol infusions was due to reduced direct ANS acti-
vation and/or via blunted epinephrine levels.
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FIG. 2. Average plasma glucagon (A), growth hormone (B), pancreatic polypeptide (C), and cortisol (D) levels (means  SE) during the ﬁnal 30
min of day 2 exercise in 22 type 1 diabetic patients (11 men/11 women). On the previous day, patients had undergone two 120-min euglycemic
clamps (anteEugly), hypoglycemic clamps (anteHypo), or euglycemic clamps with intravenous cortisol infusions at 1 g  kg
1  min
1 (anteCort1)
or 2 g  kg
1  min
1 (anteCort2) on day 1. There were signiﬁcantly fewer increments of glucagon, growth hormone, and pancreatic polypeptide
during the ﬁnal 30 min of exercise from basal levels in anteHypo and anteCort compared with anteEugly. *P < 0.05.
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mone responses to exercise were blunted after either prior
hypoglycemia or both physiologic and pharmacologic an-
tecedent cortisol elevations. The central pathways respon-
sible for hypoglycemia and corticosteroid downregulation
of neuroendocrine responses during subsequent exercise
are not known. Much recent work has demonstrated the
importance of AMP-activated protein kinase (AMPK) as a
key regulator of carbohydrate and lipid metabolism during
exercise (45). Of note are recent studies in rats demon-
strating that hypothalamic AMPK can also regulate neu-
roendocrine responses during hypoglycemia (46,47). The
study of Kola et al. (48) of humans with Cushing’s syn-
drome has determined that AMPK activity in visceral
adipose tissue is reduced by 70%, thus providing an
intriguing possibility that acute increases in corticoste-
roids may also have an effect to downregulate brain
AMPK activity. Recent work has also demonstrated the
action of central N-methyl-D-aspartate to stimulate se-
cretion of epinephrine and norepinephrine (49). Liu et
al. (50) have reported that corticosterone can rapidly
inhibit N-methyl-D-aspartate receptor activity in cul-
tured hippocampal neurons, thus providing another
possible or complimentary central molecular target for
corticosteroid downregulation of neuroendocrine and
ANS activity during subsequent exercise.
The decreased ANS and neuroendocrine responses fol-
lowing day 1 physiologic and pharmacologic cortisol ad-
ministration had profound effects on reducing metabolic
responses during day 2 exercise. During exercise, plasma
glucose levels are maintained when EGP matches the
requirements of the working muscles. Following anteced-
ent physiologic and pharmacologic elevations of cortisol,
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FIG. 3. Plasma epinephrine (A) and norepinephrine (B) levels
(means  SE) during the ﬁnal 30 min of day 2 exercise in 22 type 1
diabetic patients (11 men/11 women). On the previous day, patients
had undergone two 120-min euglycemic clamps (anteEugly), hypogly-
cemic clamps (anteHypo), or euglycemic clamps with intravenous cor-
tisol infusions at 1 g  kg
1  min
1 (anteCort1) or 2 g  kg
1  min
1
(anteCort2) on day 1. There were signiﬁcantly fewer increases of
epinephrine and norepinephrine during the ﬁnal 30 min of exercise
from basal levels in anteHypo and anteCort compared with anteEugly.
*P < 0.05.
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FIG. 4. Glucose kinetics (means  SE) during the ﬁnal 30 min of day
2 exercises in 22 type 1 diabetic patients (11 men/11 women). A:
Glucose infusion rate. B: Glucose utilization. C: EGP. On the
previous day, patients had undergone two 120-min euglycemic
clamps (anteEugly), hypoglycemic clamps, or euglycemic clamps
with intravenous cortisol infusions at 1 g  kg
1  min
1 (anteCort1)
or 2 g  kg
1  min
1 (anteCort2) on day 1. *P < 0.05 versus
anteEugly.
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day 2 exercise. Glucose infusion rates were also increased
during exercise following both doses of day 1 cortisol and
antecedent hypoglycemia. The increased glucose infusion
rates represent an aggregate reduction in counterregula-
tory responses because more glucose was required to
maintain euglycemia during exercise. Other metabolic
counterregulatory responses were also similarly reduced
following low- and high-dose cortisol and antecedent
hypoglycemia. Plasma lactate, a marker of glycogenolysis
and an important substrate for gluconeogenesis, was re-
duced following both antecedent infusions of cortisol,
presumably due to the blunted sympathetic nervous sys-
tem responses. Similarly, plasma glycerol and blood NEFA
responses, indicators of lipolysis, were also blunted by the
reduced sympathetic nervous system and growth hormone
response. Lipolysis is a key metabolic counterregulatory
mechanism during exercise. Glycerol is an important
gluconeogenic substrate, and NEFA provides energy for
the working muscle and hepatic gluconeogenesis and also
inhibits insulin’s ability to suppress hepatic glycogenolysis
(19).
Current clinical practice stresses the importance of
physical activity in diabetes management. Exercise im-
proves insulin sensitivity, helps in weight maintenance,
and lowers the risk of cardiovascular disease. Conse-
quently, growing numbers of those with type 1 diabetes
participate in different forms of exercise such as soccer,
tennis matches, outdoor hiking, or bike rides with inten-
sity and duration similar to our exercise model. The
present study, as well as our previous study (3), has shown
that prior hypoglycemia in type 1 diabetes can blunt
counterregulatory responses to subsequent exercise,
thereby increasing the risk for future hypoglycemia. This
present study provides evidence, for the ﬁrst time, that
antecedent physiologic and pharmacologic levels of cortico-
steroids on a background of hyperinsulinemic euglycemia
can produce substantial reductions in counterregulatory re-
sponses (similar to prior hypoglycemia) during subsequent
exercise in type 1 diabetes.
In summary, this study demonstrated, despite equivalent
glucose, insulin, and relative workloads, that antecedent
hypoglycemia, physiologic (anteCort1), and supraphysi-
ologic (anteCort2) levels of cortisol blunted neuroendo-
crine (growth hormone and glucagon), ANS (epinephrine,
norepinephrine, and pancreatic polypeptide), and meta-
bolic (glucose kinetics, lipolysis, and glycogenolysis)
counterregulatory responses during subsequent exercise
in individuals with type 1 diabetes. We conclude that both
prior physiologic and pharmacologic increases in cortisol
can blunt a wide spectrum of homeostatic responses
during subsequent exercise and may play a role in the
development of exercise-related counterregulatory failure
in those with type 1 diabetes.
TABLE 3
Blood lactate, alanine, -hydroxybutyrate, NEFA, and glycerol
levels during day 2 exercise euglycemic clamp studies after two
120-min euglycemic clamps (anteEugly), hypoglycemic clamps
(anteHypo), or euglycemic clamps with intravenous cortisol
infusions of 1 g  kg
1  min
1 (anteCort1) or 2 g  kg
1  min
1
(anteCort2) on day 1
Basal period
Final 30 min of
exercise
Lactate (mmol/l)
anteEugly 0.8  0.1 1.9  0.2*
anteHypo 0.8  0.1 1.3  0.1*†
anteCort1 0.7  0.1 1.1  0.2*†
anteCort2 0.9  0.1 1.9  0.1*
Alanine (mol/l)
anteEugly 329  34 418  43*
anteHypo 330  32 367  30*
anteCort1 310  60 360  40*
anteCort2 378  32 419  29*
-hydroxybutyrate (mol/l)
anteEugly 40  10 61  10*
anteHypo 48  13 66  18
anteCort1 37  55 1  10
anteCort2 50  10 40  10†
NEFA (mol/l)
anteEugly 143  25 383  72*
anteHypo 227  42‡ 298  48†
anteCort1 148  21 219  61†
anteCort2 149  28 199  39†
Glycerol (mol/l)
anteEugly 44  9 145  18*
anteHypo 48  10 111  16*†
anteCort1 77  20 111  21*†
anteCort2 50  13 100  14*†
Data are means  SEM. n  22 type 1 diabetic subjects (11 men/11
women). *Signiﬁcant difference versus basal level (P  0.05). †Sig-
niﬁcantly reduced versus anteEugly (P  0.05). ‡Signiﬁcantly in-
creased compared with other groups (P  0.05).
TABLE 4
Cardiovascular responses during day 2 exercise euglycemic
clamp studies after patients had undergone two 120-min eugly-
cemic clamps (anteEugly), hypoglycemic clamps (anteHypo), or
euglycemic clamps with intravenous cortisol infusions of 1 g 
kg
1  min
1 (anteCort1) or 2 g  kg
1  min
1 (anteCort2) on
day 1
Basal period
Final 30 min of
exercise
Heart rate (bpm)
anteEugly 70  3 136  4*
anteHypo 70  3 132  3*
anteCort1 71  2 131  4*
anteCort2 69  3 135  3*
Systolic blood pressure
(mmHg)
anteEugly 113  3 134  4*
anteHypo 115  3 136  5*
anteCort1 114  3 141  5*
anteCort2 111  3 134  4*
Diastolic blood pressure
(mmHg)
anteEugly 70  36 9  5
anteHypo 69  26 8  2
anteCort1 69  37 5  4
anteCort2 69  36 5  2
Mean blood pressure
(mmHg)
anteEugly 86  38 9  2
anteHypo 86  29 1  2
anteCort1 86  78 5  2
anteCort2 83  28 7  2
Data are means  SEM. n  22 type 1 diabetic subjects (11 men/11
women). *Signiﬁcant difference versus basal level (P  0.05).
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